×
0 0 0 0 0 0 0 0
Stockreport

Adamas Announces Final Results from the Two-Year Phase 3 Open-Label Study of GOCOVRI™ in Parkinson’s Disease Patients with Dyskinesia

ADAMAS PHARMACEUTICALS (ADMS)  More Company Research Source: GlobeNewswire
Last adamas pharmaceuticals earnings: 11/1 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.adamaspharma.com/investors
PDF -- Patients receiving GOCOVRI experienced long-term durability for up to two years -- -- Safety profile was consistent with previously-published controlled Phase 3 studies -- EMERYVILLE, Calif., April 19, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced positive data from EASE LID 2, the company’s two-year Phase 3 open-label study of GOCOVRI™ (amantadine) extended release capsules, the first and only medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. Overall, results demonstrated that GOCOVRI was generally well tolerated and the treatment effect on motor complications (dyskinesia and OFF), as measured by the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS), Part IV, was maintained for up to two years. This effect was seen in all subgroups, including [Read more]

IMPACT SNAPSHOT EVENT TIME: ADMS
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
POST NEWS RANGE
%
PRICE CHANGE

PRICE CHANGE PERCENTAGE


S&P 500 (SPX)

%

VOLUME RATIO
%

VOLUME (SHARES)
TICKS

AVG SHARES PER TRADE

Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
ADMS alerts
from News Quantified
Opt-in for
ADMS alerts

from News Quantified
Opt-in for
ADMS alerts

from News Quantified